HHS Secretary Robert F. Kennedy Jr. said this week that he may no longer allow government scientists to publish research in top medical journals.

The worse overall survival seen in transgender and gender-diverse patients may be due to treatment differences or non-breast cancer causes, researchers say.

The FDA has accepted for priority review the new drug application for sevabertinib (BAY 2927088) to treat certain patients with NSCLC.

As of this writing, the role of PD-L1 inhibitors in prostate cancer remains limited to a subset of patients with metastatic microsatellite instability-high, mismatch repair-deficient, or tumor ...

On May 20, the US Department of Health and Human Services (HHS) announced that recommending COVID-19 vaccinations for healthy children and pregnant patients would no longer be routine. “I couldn’t be ...

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

Dozens of staff at the NIH walked out of a recent town hall meeting after Director Dr Jay Bhattacharya suggested the agency may have helped fund research that caused the COVID-19 pandemic.

We need to rethink our approach in responding to cancers in our younger women patients,” said Hope S. Rugo, MD.

The results of our study suggest a concerning pattern in cancer center advertising, particularly among top-ranked institutions,” researchers wrote.

The median time to treatment initiation across all cancer types increased from 21 days in 2004 to 28 days in 2015. The median time to treatment initiation is increasing across cancer types, and this ...

Launch prices for self-administered targeted anticancer therapies have grown precipitously,” researchers wrote.

Apotex has launched the first generic version of Tasigna (nilotinib capsules), a tyrosine kinase inhibitor (TKI) approved to treat patients with chronic myeloid leukemia (CML). Apotex’s ...